Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
I'm PortAI, I can summarize articles.
Heron Therapeutics is experiencing positive growth, particularly with its products Zynrelef and Aponvie. Zynrelef has seen a 49% year-over-year revenue increase due to heightened demand and improved reimbursement access. Aponvie's growth is supported by a newly trained sales team. Despite some challenges in the oncology sector, the overall outlook remains optimistic, with strategic investments and potential inclusion in clinical guidelines. Needham has maintained a Buy rating on the stock with a $3.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments